SPY314.60-1.58 -0.50%
DIA257.29-3.43 -1.32%
IXIC10,547.75+55.25 0.53%

Chardan Capital Downgrades OncoCyte to Neutral, Lowers Price Target to $2

Chardan Capital analyst Keay Nakae downgrades OncoCyte (AMEX:OCX) from Buy to Neutral and lowers the price target from $7.75 to $2.

Benzinga · -
Chardan Capital analyst Keay Nakae downgrades OncoCyte (AMEX: OCX) from Buy to Neutral and lowers the price target from $7.75 to $2.